1-3 of 3
Douglas Vivona
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Impact of Treatment Free Remission (TFR) with Nilotinib in 2 nd Line for Chronic Myeloid Leukemia on Savings That May Fund All BCR-ABL Tests in the Brazilian Public Healthcare System during and after Nilotinib Treatment

Free
Andre Abdo, MD, Carla Maria Boquimpani, MD, Douglas Vivona, PhD, Viviane Silveira Leite, BSC, Alisson L. Matsuo, PhD, Vanessa Teich, BSC, Israel Bendit, MD PhD, Eduardo Magalhães Rego, MD PhD, Vanderson Rocha, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4760.
https://doi.org/10.1182/blood-2018-99-119200
Published: 2018
Journal Articles

ABCB1 Haplotypes Are Associated With Lower P-Gp Activity and Major Molecular Response But Do Not Affect Imatinib Plasma Levels In Chronic Myeloid Leukemia Patients

Free
Douglas Vivona, MSc, Luciene Terezina Lima, MSc, Alice C Rodrigues, Phd, Carolina Tosin Bueno, Cristiane M Gaitani, Phd, Carlos S Chiattone, MD, PhD, Vania T Hungria, MD, Maria de Lourdes L. F. Chauffaille, MD, PhD, Elvira Maria Guerra-Shinohara, PhD
Journal: Blood
Blood (2013) 122 (21): 3860.
https://doi.org/10.1182/blood.V122.21.3860.3860
Published: 2013
Journal Articles

ABCG2 and SLC22A1 Expression Are Associated with Imatinib Response in Chronic Myeloid Leukemia

Free
Douglas Vivona, MSc, Luciene Terezina Lima, Carolina Tosin Bueno, Rosario D C Hirata, PhD, Mario H Hirata, PhD, André Ducati Luchessi, PhD, Maria Zanichelli, MD, PhD, Carlos S Chiattone, MD, PhD, Elvira Maria Guerra-Shinohara, PhD
Journal: Blood
Blood (2011) 118 (21): 1422.
https://doi.org/10.1182/blood.V118.21.1422.1422
Published: 2011